Emapalumab-behandling for forventet klinisk fordel ved sepsis drevet af interferon-gamma-endotypen (EMBRACE-forsøget) (EMBRACE)
EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFNγ-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The EMBRACE trial aims to generate proof-of-concept if treatment with emapalumab, a monoclonal antibody which blocks IFNγ signaling, may improve the outcome of patients with sepsis driven by the IDS endotype. In EMBRACE, two different dose regimens of emapalumab are administered in order to: a) investigate which dose regimen may provide most of efficacy in the decrease of SOFA score, a new endpoint for sepsis suggested already by others; b) investigate which dose regimen better attains the pharmacodynamic goal of emapalumab defined as the decrease of blood CXCL9; and c) compare the efficacy of the two dose regimens with placebo treated patients.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Alexandroupoli, Grækenland
- Intensive Care Unit, Alexandroupolis University General Hospital
-
Athens, Grækenland
- 4th Department of Internal Medicine, ATTIKON University General Hospital
-
Athens, Grækenland
- Intensive Care Unit, Korgialeneio-Benakeio HRC Athens General Hospital
-
Athens, Grækenland
- 3rd University Department of Internal Medicine, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grækenland
- Intensive Care Unit I, KAT Attica General Hospital
-
Athens, Grækenland
- Intensive Care Unit of 1st University Department Respiratory Medicine, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grækenland
- Intensive Care Unit of Center for Respiratory Failure, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grækenland
- Intensive Care Unit, Asklipieio Voulas General Hospital
-
Athens, Grækenland
- Intensive Care Unit, Ippokrateio Athens General Hospital
-
Athens, Grækenland
- Intensive Care Unit, Laiko Athens General Hospital
-
Athens, Grækenland
- New Multivalent Intensive Care Unit, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grækenland
- Ηigh Dependency Unit of Department of Clinical Therapeutics, Alexandra Athens General Hospital
-
Pátrai, Grækenland
- Intensive Care Unit, Patras University General Hospital
-
Thessaloniki, Grækenland
- 1st Intensive Care Unit, G. Papanikolaou Thessaloniki General Hospital
-
Thessaloniki, Grækenland
- Department of Anesthesiology and Intensive Care, AHEPA Thessaloniki University General Hospital
-
Thessaloniki, Grækenland
- Intensive Care Unit, 424 General Military Training Hospital
-
Thessaloniki, Grækenland
- Intensive Care Unit, Aghios Dimitrios Thessaloniki General Hospital
-
Thessaloniki, Grækenland
- Intensive Care Unit, G. Gennimatas Thessaloniki General Hospital
-
Thessaloniki, Grækenland
- Intensive Care Unit, Ippokrateio Thessaloniki General Hospital
-
Thessaloniki, Grækenland
- Intensive Care Unit, Papageorgiou Thessaloniki General Hospital
-
Thessaloniki, Grækenland
- Intensive Care Unit, Theageneio Thessaloniki Cancer Hospital
-
-
Attica
-
Elefsina, Attica, Grækenland
- 1st Department of Internal Medicine, Thriasio Elefsis General Hospital
-
Kifissia, Attica, Grækenland
- Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital
-
-
Crete
-
Heraklion, Crete, Grækenland
- Intensive Care Unit, University General Hospital of Heraklion
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Provide written informed consent
- Adults (≥18 years) of male or female sex
- Diagnosis of community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), intrabdominal infection (IAI), acute pyelonephritis (AP), primary bloodstream infection (BSI) and viral respiratory infections.
- Sepsis defined by the Sepsis-3 definitions. This is defined as any new infection which is accompanied by an increase of the total baseline SOFA score by at least 2 points. The total baseline SOFA score is calculated by the medical comorbidities and by the evaluation of clinical variables before the sepsis episode in the case of hospital-acquired sepsis. In the case of patients with unknown baseline SOFA score, sepsis is defined as any new infection accompanied by total SOFA score 2 or more.
- Willingness to use effective contraceptive methods during the period from the start of the study drug to 6 months after the administration of the last dose of the study drug, in patients of reproductive age.
- Serological documentation of IDS defined as detectable blood IFNγ and CXCL9 more than 2,200 pg/ml. IFNγ and CXCL9 are measured in the central study lab by an enzyme immunosorbent assay.
- Absence of sepsis-induced immunoparalysis (SII). This is defined as ≥8000 of HLA-DR receptors on CD45/CD14-monocytes measured by flow-cytometry in the central lab using the BD™ fluorescence assay9.
Exclusion Criteria:
- Body weight more than 104 kg
- Intake of any other biological during the last 30 days prior screening except for the intake of anakinra or tocilizumab for patients with active infection by SARS-CoV-2
- Intake of any Janus kinase inhibitors during the last 30 days prior screening except for the intake of baricitinib for patients with active infection by SARS-CoV-2
- Known active infection by Mycobacterium tuberculosis or other mycobacteria. These patients may be enrolled in the trial if treatment against infection by Mycobacterium tuberculosis or other mycobacteria has been initiated
- Known active infection by VZV (varicella zoster virus) or by Histoplasma capsulatum or by Leishmania spp. These patients may be enrolled in the trial if treatment against infection by VZV or Histoplasma capsulatum has been initiated
- Known active infection by the hepatitis B virus, by the hepatitis C virus and by cytomegalovirus
- Vaccination the last 12 weeks before screening with BCG vaccine
- Vaccination with any live or attenuated live vaccine (other than BCG) the last 12 weeks before screening
- Known allergy or hypersensitivity reactions to emapalumab
- Patients living with the human immunodeficiency virus (HIV)
- Patients with stage IV solid or hematologic malignancy
- Patients with neutropenia (less than 1,000 neutrophils/mm3)
- Patients transplanted for solid organ or stem cells
- Pregnancy or lactation
- Participation in any other interventional trial the last 28 days prior to day 1
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
Standard-of-care (SoC) treatment and placebo drug. |
250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply |
|
Aktiv komparator: Emapalumab Group 1
SoC treatment and a low dose of emapalumab. |
The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Andre navne:
The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Andre navne:
|
|
Aktiv komparator: Emapalumab Group 2
SoC treatment and a high dose of emapalumab. |
The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Andre navne:
The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Decrease of SOFA score by the end-of-treatment
Tidsramme: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
The study primary endpoint is the decrease of SOFA score by the end-of-treatment (EOT). This is defined as either a) at least 1.4 points decrease of mean SOFA score calculated between days 1 and EOT from SOFA score of day 0; OR b) at least 2 points decrease of SOFA at EOT from day 0. |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Antallet af doser, der kræves i hver gruppe for at opnå SOFA-score-responset af EOT.
Tidsramme: Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
|
|
28 dages dødelighed
Tidsramme: Fra tilmelding til 28 dage efter tilmelding.
|
Fra tilmelding til 28 dage efter tilmelding.
|
|
|
The rate of serious TEAEs and non-serious TEAEs
Tidsramme: From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.
|
Comparison of the rate of serious TEAEs and non-serious TEAEs between the three groups of treatment. |
From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.
|
|
The change of the SOFA score from day 0 until day 7
Tidsramme: From enrollment (day 0) to 8 days after enrollment (day 7).
|
Comparison of the change of the SOFA score from day 0 until day 7 |
From enrollment (day 0) to 8 days after enrollment (day 7).
|
|
The change of the SOFA score from 0 until day 28
Tidsramme: From enrollment to 28 days after enrollment.
|
Comparison of the change of the SOFA score from 0 until day 28 |
From enrollment to 28 days after enrollment.
|
|
The change of the SOFA score from 0 until EOT
Tidsramme: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the change of the SOFA score from 0 until EOT |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The pharmacokinetics of emapalumab
Tidsramme: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the pharmacokinetics of emapalumab |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes.
Tidsramme: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes. |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment
Tidsramme: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Sammenligning mellem de tre grupper af behandling for den proteomiske profil over behandling
Tidsramme: Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
|
Sammenligningerne mellem de tre behandlingsgrupper for ændring af den transkriptomiske profil i forhold til behandling
Tidsramme: Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
|
Den diagnostiske ydeevne af point-of-care SepsisLoop for SII sammenlignet med det absolutte antal af HLA-DR-receptor på CD45/CD14-monocytter.
Tidsramme: Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
|
De kliniske data og biomarkørniveauer ved sengen ved screening for den potentielle udvikling af et diagnostisk værktøj, der klassificerer undersøgelsespopulationen i IDS
Tidsramme: Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
|
De prognostiske biomarkørniveauer ved screening klassificerer sepsis-populationen i forskellige undergrupper
Tidsramme: Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
Fra tilmelding til afslutning af behandling af undersøgelseslægemidlet for hver af undersøgelsesdeltagerne, varierende fra 2 til 29 dage.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studiestol: Evangelos Giamarellos-Bourboulis, Hellenic Institute for the Studies of Sepsis
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- EMBRACE
- 2024-515255-38-00 (Ctis)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .